Dose-escalated icotinib in frail, older adults patients with EGFR-mutant lung adenocarcinoma: real-world efficacy and safety in a high-risk cohort

Double-dose icotinib shows robust efficacy and manageable toxicity in high-risk older adults patients, with clinically meaningful PFS/OS. The unexpected OS benefit in L858R mutants warrants validation but suggests a dose-dependent advantage. Metastatic burden remains a key prognostic factor. These findings support dose escalation as a viable strategy for frail populations with limited access to next-generation TKIs.